ichorbio’s Ranibizumab Biosimilar – Research Grade is manufactured in a cGMP compliant facility. ichorbio offers Amazon vouchers or donations to the NC3Rs for reviews of this product: click here for more information. ichorbio: the best antibodies for in vivo research.
ichorbio’s research grade ranibizumab biosimilar is available in the following sizes:
5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of our ranibizumab biosimilar – please contact us for pricing.
Vascular endothelial growth factor A, VPF, Vascular Permeability Factor
Detects human VEGF. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Ranibizumab. This product is for research use only.
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by CHO expression system.
1.0 – 5.0 mg/ml
0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 0.75 EU/mg as determined by the LAL method
Ranibizumab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s ranibizumab biosimilar is for research use only: it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.